Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.58
-1.7%
$0.47
$0.37
$1.62
$2.81M0.45371,794 shs72,565 shs
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
$0.00
$0.00
$0.00
$0.00
N/A-2.354,409 shsN/A
LLIT
Lianluo Smart
$0.79
$9.91
$2.76
$17.14
$1.74M0.161.04 million shs117,181 shs
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
$0.58
$0.22
$2.40
$997K0.658.25 million shs1.89 million shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$1.67
+4.1%
$1.85
$0.97
$5.09
$7.12M0.5931,137 shs5,262 shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynatronics Co. stock logo
DYNT
Dynatronics
+9.38%+0.82%+28.78%+15.49%-60.68%
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
0.00%0.00%-80.00%-84.62%-92.86%
LLIT
Lianluo Smart
+5.30%+10.76%-24.26%-1.50%-22.81%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
0.00%0.00%0.00%-49.26%-74.34%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-1.84%-9.35%-16.67%-16.32%-53.60%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dynatronics Co. stock logo
DYNT
Dynatronics
0.8328 of 5 stars
3.03.00.00.00.60.00.6
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
LLIT
Lianluo Smart
N/AN/AN/AN/AN/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
1.5197 of 5 stars
3.54.00.00.01.90.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dynatronics Co. stock logo
DYNT
Dynatronics
2.00
Hold$3.80560.41% Upside
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/AN/AN/AN/A
LLIT
Lianluo Smart
N/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.00
Buy$10.00500.60% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dynatronics Co. stock logo
DYNT
Dynatronics
$40.61M0.07N/AN/A$2.19 per share0.26
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/AN/AN/AN/AN/AN/A
LLIT
Lianluo Smart
$380K4.57N/AN/A($0.59) per share-1.33
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/A$6.48 per shareN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$4.91M1.45N/AN/A($0.30) per share-5.55

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dynatronics Co. stock logo
DYNT
Dynatronics
-$4.97M-$1.38N/AN/A-14.13%-54.88%-16.14%5/9/2024 (Estimated)
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/AN/A0.00N/AN/AN/AN/AN/A
LLIT
Lianluo Smart
-$4.45MN/A0.00N/AN/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$13.32M-$33.76N/AN/AN/A-271.04%-805.57%-97.73%4/25/2024 (Estimated)

Latest DYNT, PSTV, HDII, LLIT, and NVIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/5/2024Q4 2023
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.78-$0.70+$0.08-$0.70$1.26 million$1.31 million
2/7/2024Q2 2024
Dynatronics Co. stock logo
DYNT
Dynatronics
N/A-$0.27-$0.27-$0.27N/A$8.15 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/AN/AN/AN/AN/A
LLIT
Lianluo Smart
N/AN/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dynatronics Co. stock logo
DYNT
Dynatronics
0.21
1.41
0.67
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/AN/AN/A
LLIT
Lianluo Smart
N/A
2.42
2.17
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/A
14.30
14.30
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
0.92
0.92

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/A
LLIT
Lianluo Smart
28.75%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
13.78%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Dynatronics Co. stock logo
DYNT
Dynatronics
1544.88 million4.44 millionNot Optionable
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
2,017N/AN/ANot Optionable
LLIT
Lianluo Smart
62.21 millionN/ANot Optionable
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
63.11 million3.03 millionNot Optionable
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
204.28 million4.18 millionNot Optionable

DYNT, PSTV, HDII, LLIT, and NVIV Headlines

SourceHeadline
Plus Therapeutics (NASDAQ:PSTV) Trading Up 1.8%Plus Therapeutics (NASDAQ:PSTV) Trading Up 1.8%
americanbankingnews.com - April 23 at 1:48 AM
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of DefenseMicro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
finance.yahoo.com - April 22 at 10:35 AM
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of DefensePlus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
globenewswire.com - April 22 at 7:00 AM
Plus Therapeutics, Inc. (PSTV)Plus Therapeutics, Inc. (PSTV)
finance.yahoo.com - April 19 at 12:11 AM
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management TeamNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
finance.yahoo.com - April 9 at 7:57 AM
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.
globenewswire.com - April 9 at 7:00 AM
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual ConferencePlus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
finance.yahoo.com - March 27 at 10:29 AM
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell DiagnosticPlus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
finance.yahoo.com - March 25 at 8:51 AM
Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry TailwindsBuy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds
markets.businessinsider.com - March 23 at 7:41 AM
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal MetastasesPlus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
finance.yahoo.com - March 11 at 9:16 AM
Plus Therapeutics Full Year 2023 Earnings: Beats ExpectationsPlus Therapeutics Full Year 2023 Earnings: Beats Expectations
finance.yahoo.com - March 7 at 10:46 AM
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call TranscriptPlus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 7 at 10:46 AM
Q4 2023 Plus Therapeutics Inc Earnings CallQ4 2023 Plus Therapeutics Inc Earnings Call
finance.yahoo.com - March 6 at 6:24 PM
PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023
investorplace.com - March 5 at 10:33 PM
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue EstimatesPlus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
zacks.com - March 5 at 6:36 PM
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsPlus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
globenewswire.com - March 5 at 4:05 PM
IMUNON stock rallies 19% on early results for COVID-19 vaccineIMUNON stock rallies 19% on early results for COVID-19 vaccine
msn.com - February 29 at 1:33 PM
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
finance.yahoo.com - February 27 at 8:49 AM
Plus Therapeutics Inc PSTVPlus Therapeutics Inc PSTV
morningstar.com - February 21 at 6:55 PM
Plus Therapeutics Inc [PSTV] Stock sold by Insider HEDRICK MARC H for $4053.0Plus Therapeutics Inc [PSTV] Stock sold by Insider HEDRICK MARC H for $4053.0
knoxdaily.com - January 1 at 10:51 PM
Plus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024Plus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024
finanznachrichten.de - December 18 at 1:46 PM
Plus Updates Financial and Cash Guidance for 2024Plus Updates Financial and Cash Guidance for 2024
finance.yahoo.com - December 18 at 8:46 AM
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker AnalysesPlus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
finance.yahoo.com - December 12 at 10:20 AM
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)
markets.businessinsider.com - November 29 at 8:56 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Dynatronics logo

Dynatronics

NASDAQ:DYNT
Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.
Hypertension Diagnostics logo

Hypertension Diagnostics

OTCMKTS:HDII
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada.

Lianluo Smart

NASDAQ:LLIT
Lianluo Smart Limited, together with its subsidiaries, designs, develops, markets, and distributes medical products primarily in China and internationally. The company offers medical devices, including wearable sleep respiratory solutions, general hospital products, medical compressors, and related supporting products. It also provides technical services in relation to the detection and analysis of obstructive sleep apnea syndrome to hospitals and medical centers through medical wearable devices. In addition, the company distributes medical products, such as sleep apnea machines. Lianluo Smart Limited sells its products primarily through distributors; and directly to hospitals, physical examination centers, and sleep centers, as well as to individual consumers. The company was formerly known as Dehaier Medical Systems Limited and changed its name to Lianluo Smart Limited in November 2016. Lianluo Smart Limited was incorporated in 2003 and is headquartered in Beijing, China.
InVivo Therapeutics logo

InVivo Therapeutics

NASDAQ:NVIV
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.
Plus Therapeutics logo

Plus Therapeutics

NASDAQ:PSTV
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.